Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.

Autor: Penny TR; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia. tayla.penny@hudson.org.au.; Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia. tayla.penny@hudson.org.au., Jenkin G; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia., Miller SL; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia., McDonald CA; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia.
Jazyk: angličtina
Zdroj: Stem cell research & therapy [Stem Cell Res Ther] 2024 Jul 29; Vol. 15 (1), pp. 234. Date of Electronic Publication: 2024 Jul 29.
DOI: 10.1186/s13287-024-03830-0
Abstrakt: Umbilical cord blood (UCB) is a rich source of beneficial stem and progenitor cells with known angiogenic, neuroregenerative and immune-modulatory properties. Preclinical studies have highlighted the benefit of UCB for a broad range of conditions including haematological conditions, metabolic disorders and neurological conditions, however clinical translation of UCB therapies is lacking. One barrier for clinical translation is inadequate cell numbers in some samples meaning that often a therapeutic dose cannot be achieved. This is particularly important when treating adults or when administering repeat doses of cells. To overcome this, UCB cell expansion is being explored to increase cell numbers. The current focus of UCB cell expansion is CD34+ haematopoietic stem cells (HSCs) for which the main application is treatment of haematological conditions. Currently there are 36 registered clinical trials that are examining the efficacy of expanded UCB cells with 31 of these being for haematological malignancies. Early data from these trials suggest that expanded UCB cells are a safe and feasible treatment option and show greater engraftment potential than unexpanded UCB. Outside of the haematology research space, expanded UCB has been trialled as a therapy in only two preclinical studies, one for spinal cord injury and one for hind limb ischemia. Proteomic analysis of expanded UCB cells in these studies showed that the cells were neuroprotective, anti-inflammatory and angiogenic. These findings are also supported by in vitro studies where expanded UCB CD34+ cells showed increased gene expression of neurotrophic and angiogenic factors compared to unexpanded CD34+ cells. Preclinical evidence demonstrates that unexpanded CD34+ cells are a promising therapy for neurological conditions where they have been shown to improve multiple indices of injury in rodent models of stroke, Parkinson's disease and neonatal hypoxic ischemic brain injury. This review will highlight the current application of expanded UCB derived HSCs in transplant medicine, and also explore the potential use of expanded HSCs as a therapy for neurological conditions. It is proposed that expanded UCB derived CD34+ cells are an appropriate cellular therapy for a range of neurological conditions in children and adults.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje